Advaxis (NASDAQ:ADXS) had its price objective reduced by research analysts at Cantor Fitzgerald from $19.00 to $5.00 in a research note issued to investors on Tuesday. The firm currently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 153.81% from the company’s current price.

Several other research firms have also recently weighed in on ADXS. ValuEngine raised shares of Advaxis from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. HC Wainwright set a $23.00 target price on shares of Advaxis and gave the company a “buy” rating in a research report on Wednesday, December 27th.

How to Become a New Pot Stock Millionaire

Advaxis (NASDAQ ADXS) opened at $1.97 on Tuesday. Advaxis has a twelve month low of $1.75 and a twelve month high of $9.55. The firm has a market cap of $81.84, a P/E ratio of -0.83 and a beta of 1.06.

Advaxis (NASDAQ:ADXS) last released its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.06. Advaxis had a negative net margin of 940.64% and a negative return on equity of 131.78%. The firm had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $3.03 million. analysts anticipate that Advaxis will post -2.36 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in Advaxis by 7.2% during the second quarter. Vanguard Group Inc. now owns 1,782,990 shares of the biotechnology company’s stock valued at $11,572,000 after buying an additional 119,980 shares during the period. State Street Corp grew its position in Advaxis by 7.8% during the second quarter. State Street Corp now owns 670,134 shares of the biotechnology company’s stock valued at $4,352,000 after buying an additional 48,485 shares during the period. Renaissance Technologies LLC bought a new stake in Advaxis during the fourth quarter valued at approximately $1,398,000. Deutsche Bank AG grew its position in Advaxis by 1,200.1% during the fourth quarter. Deutsche Bank AG now owns 467,324 shares of the biotechnology company’s stock valued at $1,326,000 after buying an additional 431,379 shares during the period. Finally, Northern Trust Corp grew its position in Advaxis by 4.4% during the second quarter. Northern Trust Corp now owns 456,817 shares of the biotechnology company’s stock valued at $2,965,000 after buying an additional 19,434 shares during the period. Institutional investors own 29.79% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with's FREE daily email newsletter.